New York University

New York City, New York, US
New York University banner
Private research university in New York City with an integrated academic medical center, co‑located engineering and computing hubs in Brooklyn and Manhattan, startup incubators, and dedicated tech transfer. NYC proximity to major industries speeds partnership and piloting.
New York University is a comprehensive private research university anchored in New York City, enrolling a large, diverse student body and operating a global network of campuses. Corporate engagement is enabled by co‑located engineering and computing hubs in Brooklyn and Manhattan with shared labs and facilities for prototyping and field pilots. Integration with a major hospital system supports clinical translation, IRB processes, and access to real‑world data under stringent governance. Proximity to leading industries and a mature sponsored‑research function streamline scoping, NDAs, MSAs, and talent pipelines. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, and DOD, and a dedicated technology transfer office manages IP, licensing, and startup creation.

Top industry applications

Top industry applications are determined by Halo’s AI based on publication data and partnering evidence and are not influenced by the university. Read methodology.
Medicine
Medical diagnostics
NYU researchers are advancing clinical diagnostics with genomic profiling, liquid biopsies, multiplex cytokine assays, and AI analysis of pathology, imaging, and blood biomarkers. These tools aim to detect cancer, autoimmune disease, neurological disorders, and critical illness earlier and more accurately, creating opportunities for scalable laboratory tests, point-of-care platforms, and clinical decision-support software.
Medicine
Oncology & cancer therapeutics
NYU researchers are advancing precision oncology through tumor genomic profiling, patient-derived organoids, liquid biopsies, AI pathology, and biomarkers that predict treatment response or resistance. Their work also targets hard-to-treat cancers with next-generation immunotherapies, KRAS and metabolic inhibitors, antibody-drug conjugates, radiopharmaceuticals, and localized drug-delivery systems—creating opportunities for deployable diagnostics and more effective therapies.
Medicine
Pharmaceuticals and drug delivery
NYU researchers are developing biodegradable implants, light-responsive nanoparticles, polymeric intranasal vaccines, and nanoencapsulated medicines for localized, sustained, and safer drug delivery. These platforms target cancer, respiratory infections, gout, and chronic pain, creating commercial opportunities in precision therapeutics, vaccine delivery, and non-addictive analgesics.
Medicine
Medical imaging
NYU researchers are developing AI-enabled MRI reconstruction, motion correction, low-field enhancement, and uncertainty assessment to make scans faster, more accessible, and safer for clinical use. Their imaging models support earlier cancer detection, quantitative disease monitoring, and automated triage, creating opportunities for deployable radiology software, scanner upgrades, and scalable diagnostic services.
Digital & computing technologies
Artificial intelligence & machine learning
NYU researchers are developing practical AI for healthcare, finance, enterprise search, retail, autonomous systems, and scientific discovery, including clinical decision support, document processing, personalized recommendations, and agentic workflows. Their work also targets deployment barriers such as cost, latency, privacy, reliability, bias, and cybersecurity, creating opportunities for scalable AI products that businesses can trust.
Medicine
Cardiovascular health
NYU researchers are developing AI-enabled ECG interpretation, coronary CT plaque analysis, and EHR tools for real-time cardiogenic-shock screening and hypertension management. These scalable technologies support earlier diagnosis, personalized risk prediction, and remote care—creating opportunities for medical-device, digital-health, imaging, and clinical decision-support markets.
Medicine
Infectious disease & antimicrobials
NYU researchers study how bacteria such as Staphylococcus aureus disable the immune system, and develop synthetic anti-infective compounds and tuberculosis diagnostics. A five-year research partnership with Janssen on S. aureus toxins produced jointly filed patents, Maxwell Biosciences licensed NYU's anti-infective platform in 2021 and has since raised venture funding, and TB Biosciences was founded on NYU-licensed tuberculosis diagnostic technology. Companies working on new antimicrobials can draw on established licensing routes and labs experienced in industry-sponsored infection research.
Medicine
Surgical technologies
NYU surgeons and engineers are developing augmented-reality surgical navigation, radar-based tracking for orthopedic robotics, and 3D visualization tools for planning complex procedures. Medivis, founded by NYU-trained physicians, raised a $20 million Series A and holds FDA clearances for augmented-reality navigation including cranial neurosurgery, and Caira Surgical, co-founded by an NYU Langone orthopedic surgeon, has raised a seed round and a $10 million Series A. NYU Langone's surgical departments give medtech companies clinical collaborators for developing and testing new devices.
Last updated by Halo AI Oct 13, 2026. Please verify key information.
OpenAlexOpenAlex
For general inquiries
Have a specific need?
Post a free request to New York University faculty.
Halo home
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.